Prelude Therapeutics Stock Forecast - Naive Prediction
| PRLD Stock | USD 2.03 0.18 8.14% |
The Naive Prediction forecasted value of Prelude Therapeutics on the next trading day is expected to be 1.62 with a mean absolute deviation of 0.22 and the sum of the absolute errors of 13.34. Prelude Stock Forecast is based on your current time horizon. Investors can use this forecasting interface to forecast Prelude Therapeutics stock prices and determine the direction of Prelude Therapeutics's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Prelude Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time the rsi of Prelude Therapeutics' share price is below 20 indicating that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter (0.30) | EPS Estimate Current Year (1.27) | EPS Estimate Next Year (1.15) | Wall Street Target Price 4 | EPS Estimate Current Quarter (0.35) |
Using Prelude Therapeutics hype-based prediction, you can estimate the value of Prelude Therapeutics from the perspective of Prelude Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Prelude Therapeutics using Prelude Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Prelude using crowd psychology based on the activity and movement of Prelude Therapeutics' stock price.
Prelude Therapeutics Short Interest
A significant increase or decrease in Prelude Therapeutics' short interest from the previous month could be a good indicator of investor sentiment towards Prelude. Short interest can provide insight into the potential direction of Prelude Therapeutics stock and how bullish or bearish investors feel about the market overall.
200 Day MA 1.2692 | Short Percent 0.1955 | Short Ratio 3.09 | Shares Short Prior Month 1.3 M | 50 Day MA 1.9271 |
Prelude Therapeutics Hype to Price Pattern
Investor biases related to Prelude Therapeutics' public news can be used to forecast risks associated with an investment in Prelude. The trend in average sentiment can be used to explain how an investor holding Prelude can time the market purely based on public headlines and social activities around Prelude Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Prelude Therapeutics Implied Volatility | 3.59 |
Prelude Therapeutics' implied volatility exposes the market's sentiment of Prelude Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Prelude Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Prelude Therapeutics stock will not fluctuate a lot when Prelude Therapeutics' options are near their expiration.
The Naive Prediction forecasted value of Prelude Therapeutics on the next trading day is expected to be 1.62 with a mean absolute deviation of 0.22 and the sum of the absolute errors of 13.34. Prelude Therapeutics after-hype prediction price | USD 2.9 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Prelude Therapeutics to cross-verify your projections. Open Interest Against 2026-03-20 Prelude Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Prelude Therapeutics' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Prelude Therapeutics' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Prelude Therapeutics stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Prelude Therapeutics' open interest, investors have to compare it to Prelude Therapeutics' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Prelude Therapeutics is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Prelude. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Prelude Therapeutics Additional Predictive Modules
Most predictive techniques to examine Prelude price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Prelude using various technical indicators. When you analyze Prelude charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Prelude Therapeutics Cash Forecast
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Prelude Therapeutics' financial statements to predict how it will affect future prices.
Cash | First Reported 2019-03-31 | Previous Quarter 25.8 M | Current Value 47.5 M | Quarterly Volatility 103.4 M |
Prelude Therapeutics Naive Prediction Price Forecast For the 24th of January
Given 90 days horizon, the Naive Prediction forecasted value of Prelude Therapeutics on the next trading day is expected to be 1.62 with a mean absolute deviation of 0.22, mean absolute percentage error of 0.13, and the sum of the absolute errors of 13.34.Please note that although there have been many attempts to predict Prelude Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Prelude Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Prelude Therapeutics Stock Forecast Pattern
| Backtest Prelude Therapeutics | Prelude Therapeutics Price Prediction | Buy or Sell Advice |
Prelude Therapeutics Forecasted Value
In the context of forecasting Prelude Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Prelude Therapeutics' downside and upside margins for the forecasting period are 0.02 and 24.08, respectively. We have considered Prelude Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Prelude Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Prelude Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 116.0327 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.2187 |
| MAPE | Mean absolute percentage error | 0.1133 |
| SAE | Sum of the absolute errors | 13.3407 |
Predictive Modules for Prelude Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Prelude Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Prelude Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Prelude Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Prelude Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Prelude Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Prelude Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Prelude Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Prelude Therapeutics' historical news coverage. Prelude Therapeutics' after-hype downside and upside margins for the prediction period are 0.15 and 25.36, respectively. We have considered Prelude Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Prelude Therapeutics is abnormally volatile at this time. Analysis and calculation of next after-hype price of Prelude Therapeutics is based on 3 months time horizon.
Prelude Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Prelude Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Prelude Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Prelude Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.20 | 22.46 | 0.57 | 0.41 | 7 Events / Month | 7 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.03 | 2.90 | 31.25 |
|
Prelude Therapeutics Hype Timeline
Prelude Therapeutics is at this time traded for 2.03. The entity has historical hype elasticity of -0.57, and average elasticity to hype of competition of -0.41. Prelude is expected to increase in value after the next headline, with the price projected to jump to 2.9 or above. The average volatility of media hype impact on the company the price is over 100%. The price growth on the next news is projected to be 31.25%, whereas the daily expected return is at this time at 2.2%. The volatility of related hype on Prelude Therapeutics is about 12140.54%, with the expected price after the next announcement by competition of 1.62. Prelude Therapeutics currently holds 18.02 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Prelude Therapeutics has a current ratio of 15.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Prelude Therapeutics' use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next expected press release will be in about 7 days. Check out Historical Fundamental Analysis of Prelude Therapeutics to cross-verify your projections.Prelude Therapeutics Related Hype Analysis
Having access to credible news sources related to Prelude Therapeutics' direct competition is more important than ever and may enhance your ability to predict Prelude Therapeutics' future price movements. Getting to know how Prelude Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Prelude Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PYXS | Pyxis Oncology | (0.12) | 8 per month | 0.00 | (0.06) | 17.05 | (15.41) | 70.66 | |
| OBIO | Orchestra BioMed Holdings | 0.02 | 9 per month | 3.85 | 0.07 | 10.54 | (6.20) | 25.95 | |
| ENTA | Enanta Pharmaceuticals | 0.09 | 9 per month | 2.72 | 0.03 | 5.67 | (4.04) | 15.79 | |
| CRBU | Caribou Biosciences | (0.02) | 10 per month | 0.00 | (0.22) | 6.86 | (8.76) | 20.16 | |
| IVA | Inventiva Sa | (0.25) | 7 per month | 6.66 | 0.09 | 10.82 | (6.48) | 34.91 | |
| TNYA | Tenaya Therapeutics | (0.04) | 6 per month | 0.00 | (0.16) | 9.02 | (11.04) | 51.79 | |
| AVTX | Avalo Therapeutics | (1.83) | 8 per month | 4.32 | 0.02 | 10.71 | (6.28) | 25.25 | |
| EPRX | Eupraxia Pharmaceuticals Common | 0.22 | 25 per month | 2.94 | 0.15 | 6.98 | (4.46) | 24.61 | |
| IMRX | Immuneering Corp | (0.03) | 10 per month | 8.71 | 0.02 | 8.12 | (7.44) | 67.18 | |
| FHTX | Foghorn Therapeutics | 0.11 | 10 per month | 4.19 | 0.13 | 9.16 | (5.56) | 31.12 |
Other Forecasting Options for Prelude Therapeutics
For every potential investor in Prelude, whether a beginner or expert, Prelude Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Prelude Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Prelude. Basic forecasting techniques help filter out the noise by identifying Prelude Therapeutics' price trends.Prelude Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prelude Therapeutics stock to make a market-neutral strategy. Peer analysis of Prelude Therapeutics could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Prelude Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Prelude Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Prelude Therapeutics shares will generate the highest return on investment. By undertsting and applying Prelude Therapeutics stock market strength indicators, traders can identify Prelude Therapeutics entry and exit signals to maximize returns.
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 2.03 | |||
| Day Typical Price | 2.03 | |||
| Price Action Indicator | (0.09) | |||
| Period Momentum Indicator | (0.18) |
Prelude Therapeutics Risk Indicators
The analysis of Prelude Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Prelude Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting prelude stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 9.79 | |||
| Semi Deviation | 11.11 | |||
| Standard Deviation | 21.68 | |||
| Variance | 470.03 | |||
| Downside Variance | 189.94 | |||
| Semi Variance | 123.35 | |||
| Expected Short fall | (11.27) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Prelude Therapeutics
The number of cover stories for Prelude Therapeutics depends on current market conditions and Prelude Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Prelude Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Prelude Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Prelude Therapeutics Short Properties
Prelude Therapeutics' future price predictability will typically decrease when Prelude Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Prelude Therapeutics often depends not only on the future outlook of the potential Prelude Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Prelude Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 75.8 M | |
| Cash And Short Term Investments | 133.6 M |
Check out Historical Fundamental Analysis of Prelude Therapeutics to cross-verify your projections. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prelude Therapeutics. If investors know Prelude will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prelude Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prelude Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prelude Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prelude Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.